,
your personalized virtual assistant to find clinical trials. Go head, 
Paul Richardson, MD
Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 Dana Faber Cancer InstituteBoston, Massachusetts - 02115 Dana-Farber Cancer Institute/Brigham & Women's ...Boston, Massachusetts - 02115 |
- CLINICAL TRIALS 5
- CONDITIONS4
- INTERVENTIONS7
- SINCE2005
A Phase 1b/2 Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
April 2008 - September 2011
MTD Safety and Efficacy of CC-4047 Alone With Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
May 2008 - September 2011
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
January 2009 - November 2010
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
April 2005 - September 2011
Phase 1 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
March 2007 - June 2009
Multiple Myeloma
Neoplasms, Plasma Cell
Bone Diseases
Hematologic Neoplasms
Placebo
Dexamethasone
Elotuzumab (Huluc63)
Cc-4047
Npi-0052
Bhq880
Dendritic Cell Tumor Fusion
